In patient-derived tumor xenografts, HER2 CAR-T cells effectively inhibited CRC progression and demonstrated potent immunotherapeutic effects against metastatic CRC.63 In addition, tumor microenvironment (TME)–associated markers could be alternatives for CAR-T cell therapy in CRCs. This evidence concerns the gene ERBB2 and neoplasm.